Skip to main
GPCR

GPCR Stock Forecast & Price Target

GPCR Analyst Ratings

Based on 12 analyst ratings
Strong Buy
Strong Buy 58%
Buy 42%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Structure Therapeutics is positioned for success in the growing market for oral obesity drugs with their promising drug aleniglipron, which has shown similar efficacy to injectable drugs and has a successful dose strategy to reduce adverse events. The company's consideration of dose selection and competitor Phase 3 designs, as well as their exploration of partnerships and acquisitions, further supports their potential for success. While there are potential risks, Structure's positive data and upcoming milestones make the stock an attractive investment opportunity.

Bears say

Structure Therapeutics is a clinical-stage biopharmaceutical company that leverages structure-based drug discovery and computational chemistry to develop small molecule therapeutics for chronic diseases with unmet medical needs. Its market cap, which is currently at $4 billion, is in line with its strong Phase 2b data and defined path to Phase 3. However, potential risks such as obesity study results and strategic partnerships could have a negative impact on the company's outlook. Additionally, competition in the incretin space and concerns about tolerability may hinder the product's success in a market driven by instant gratification. The company may also face antitrust scrutiny and potential hurdles in commercial positioning.

GPCR has been analyzed by 12 analysts, with a consensus rating of Strong Buy. 58% of analysts recommend a Strong Buy, 42% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Structure Therapeutics Inc (GPCR) Forecast

Analysts have given GPCR a Strong Buy based on their latest research and market trends.

According to 12 analysts, GPCR has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $104.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $104.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Structure Therapeutics Inc (GPCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.